Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) - PubMed
3 months ago
- #Clinical Trial
- #BCG Therapy
- #Bladder Cancer
- The study compared BCG + MM versus BCG alone in BCG-naïve NMIBC patients.
- 501 participants were randomized (249 to BCG + MM, 252 to BCG alone).
- No significant difference in disease-free survival (DFS) between the two groups (2-year DFS: 75% vs 71%).
- BCG + MM required 39% fewer BCG doses and had fewer treatment discontinuations.
- Grade 3-5 adverse events were slightly higher in the BCG + MM group (43 vs 37).
- BCG + MM could be a pragmatic alternative to BCG alone, helping mitigate BCG shortages.